CorMedix (CRMD) Competitors

CorMedix (NASDAQ:CRMD) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Which has preferable valuation and earnings, CRMD or NAMS?

CorMedix has higher earnings, but lower revenue than NewAmsterdam Pharma. CorMedix is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$43.47M	9.37	-$46.34M	-$0.33	-20.33
NewAmsterdam Pharma	$45.56M	54.01	-$176.94M	-$2.60	-8.62

Which has more risk & volatility, CRMD or NAMS?

CorMedix has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Do analysts rate CRMD or NAMS?

CorMedix currently has a consensus price target of $15.14, suggesting a potential upside of 125.68%. NewAmsterdam Pharma has a consensus price target of $43.33, suggesting a potential upside of 93.37%. Given CorMedix's stronger consensus rating and higher probable upside, equities research analysts clearly believe CorMedix is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to CRMD or NAMS?

In the previous week, CorMedix had 23 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 27 mentions for CorMedix and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.66 beat CorMedix's score of 0.47 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of CRMD or NAMS?

34.2% of CorMedix shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is CRMD or NAMS more profitable?

NewAmsterdam Pharma's return on equity of 0.00% beat CorMedix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	N/A	-79.21%	-64.68%
NewAmsterdam Pharma	N/A	N/A	N/A

Does the MarketBeat Community believe in CRMD or NAMS?

CorMedix received 5 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.30% of users gave NewAmsterdam Pharma an outperform vote while only 79.49% of users gave CorMedix an outperform vote.

Company	Underperform	Outperform
CorMedix	Outperform Votes 31 79.49%	Underperform Votes 8 20.51%
NewAmsterdam Pharma	Outperform Votes 26 96.30%	Underperform Votes 1 3.70%

Summary

CorMedix beats NewAmsterdam Pharma on 10 of the 18 factors compared between the two stocks.